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Summary 
Treatment guidance for non-multidrug resistant (MDR) rifampicin resistant (RMP-R) 
tuberculosis (TB) is variable. We aimed to undertake a systematic review and meta-analysis 
of the randomised controlled trial (RCT) data behind such guidelines to identify the most 
efficacious treatment regimens. Ovid MEDLINE, the Web of Science, and EMBASE were 
mined using search terms for TB, drug therapy, and RCTs. Despite 12,604 records being 
retrieved, only three studies reported treatment outcomes by regimen for patients with non-
MDR RMP-R disease, preventing meta-analysis. Our systematic review highlights a 
substantial gap in the literature regarding evidence-based treatment regimens for RMP-R 
TB.  
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Introduction 
The World Health Organization (WHO) estimates that, in 2014, 1.1% of tuberculosis (TB) 
patients had rifampicin resistant (RMP-R) disease without additional resistance to isoniazid 
(INH) i.e. not multidrug resistant (MDR).1 This equates to approximately 40,000 notified 
pulmonary TB patients with RMP-R strains.1  
 
Treatment guidance for non-MDR RMP-R TB is diverse. The WHO stated in 2011 that ‘[t]he 
detection of rifampicin resistance by Xpert MTB/RIF usually suffices to start a patient on a 
second-line TB regimen, subject to confirmatory testing in situations with low rifampicin 
resistance’.2 In 2003 the American Thoracic Society (ATS) recommended a regimen of INH, 
pyrazinamide (PZA) and ethambutol (EMB) for nine to 12 months (with the addition of a 
fluoroquinolone for patients with more extensive disease) for RMP-R TB.3 UK National 
Institute for Care Excellence (NICE) guidelines, developed 2012-2015, endorse following 
WHO MDR-TB treatment guidance.2;4  
 
A previous review of 12 British Medical Research Council randomised controlled trials 
(RCTs) containing patients with drug resistant disease, published by Mitchison et al. in 1986, 
demonstrated that RMP-R was related to worse treatment outcomes.5 Some of the included 
patients had MDR disease, however, and no formal meta-analysis comparing the efficacy of 
different regimens was undertaken. 
 
Given the variability in treatment guidance, we aimed to undertake an up-to-date systematic 
review and meta-analysis of RCTs of treatment regimens for RMP monoresistant disease. 
 
Study population and methods 
Figure 1 and Online Appendix 1 document our literature search. Reference lists of included 
papers and review articles were also mined. RCTs of antimicrobial regimens for TB patients 
indexed by 21st January 2015 were included, provided that either treatment outcome or 
relapses post-treatment could specifically be extracted for patients with RMP monoresistant 
disease. TB deaths were also extracted. Studies were not excluded by language. HRS 
screened all of (and H-AH 10% of) the retrieved records. Both reviewers independently 
undertook the final stage of full text screening and extraction into a standardised pre-
designed spreadsheet. Discrepancies were resolved by discussion; other authors were 
consulted when required. Both reviewers assessed study quality.6 Studies were deemed to 
have a high risk of bias from selective reporting if the overall RCT was not of patients with 
drug resistant strains. The thresholds for the attrition criteria were- ≥10% losses during follow 
up across all study participants (ignoring exclusions for not fulfilling inclusion criteria), or 
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≥10% absolute difference in losses between study arms. Where drug resistance was not the 
primary focus of a study, attrition was assessed for the entire study population. 
 
This review was registered on PROSPERO (CRD42014015025). As this was a systematic 
review ethical approval and informed consent were not required. 
 
Results 
Of 12,604 de-duplicated publications found, only three reported outcomes specifically for 
patients with RMP monoresistant disease and had more than one such patient in their trial 
(Table 1, Figure 1). Consensus between the two reviewers on publications for inclusion was 
100%. No study focussed solely on the treatment of patients with drug resistant strains or 
had more than five RMP-R patients for whom outcomes were reported. All studies recruited 
patients with pulmonary disease and utilised RMP in every treatment arm. None trialled the 
treatment regimens recommended by the WHO, NICE or ATS. The risk of bias for various 
quality domains was frequently unknown (Table 1). 
 
The Hong Kong Chest Service study contained two relevant patients for whom outcome data 
were extractable, one per regimen arm.7 Both arms treated patients with INH, PZA, RMP, 
streptomycin (STM) for four months, one with a daily dosing schedule and one thrice weekly. 
Both patients had negative cultures at the end of chemotherapy, but the individual with daily 
dosing relapsed post-treatment. Jindani et al. contained five patients across two eight month 
arms of EMB, INH, PZA, RMP followed by EMB, INH (one dosed daily and one with a thrice 
weekly intensive phase but daily dosing thereafter) and one six month arm of EMB, INH, 
PZA, RMP followed by INH, RMP (dosed daily).8 None failed treatment (ascertained by 
culture status or needing to change treatment) or relapsed post-treatment. The Tuberculosis 
Research Centre study contained two relevant patients, one in each of two study arms (two 
six month EMB, INH, PZA, RMP then INH, RMP regimens with two versus three month 
intensive phases).9 No unfavourable outcomes (culture status at the end of treatment, 
treatment change required, clinical deterioration, died of TB) were reported by the end of 
treatment. Given the small amount of available data meta-analysis of relative regimen 
efficacy was not possible. 
 
Discussion 
This systematic review, which sought to assess the relative efficacy of different treatment 
regimens for RMP monoresistant TB disease, highlights a substantial gap in the literature, 
perhaps because such studies are perceived as challenging or relatively low priority. This is 
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despite our extending and updating of the work of Mitchison et al. from 1986, which included 
only two patients with RMP monoresistance.5  
 
Our inclusion criteria were limited to RCTs; observational studies can provide useful 
information in the absence of adequately powered trials. A literature search (Online 
Appendix 2) undertaken on the 11th of January 2016 identified very few relevant 
observational publications. For example, Meyssonnier et al. undertook a retrospective cohort 
study of treatment regimens and outcomes for non-MDR RMP-R in France, 2005-2010; with 
only 49 patients few conclusions could be drawn.10 Such studies are more subject to bias 
than RCTs, and frequently insufficient for the formulation of evidence-based guidance. 
 
It is unclear if current WHO guidance results in over-treatment of non-MDR RMP-R disease; 
indeed, it may be appropriate if weaker regimens are inadequate. Lengthy treatments with 
unpleasant adverse events can reduce patient adherence, increasing the likelihood of further 
drug resistance and onward transmission to others. Therefore, given the duration and 
toxicity of MDR-TB regimens, minimising unnecessary exposure of non-MDR RMP-R 
patients to such treatments, whilst ensuring an effective cure, is a priority.  
 
Conclusions 
To provide a solid scientific foundation for global treatment guidance, and given current data 
sparsity, we recommend that a properly powered RCT is undertaken to answer unresolved 
questions concerning the efficaciousness of different treatment regimens for RMP 
monoresistant disease. 
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Table 1: Studies fulfilling the inclusion criteria 
    Outcomes for 
rifampicin 
monoresistant 
patients 
Quality assessment: risk of bias from… 
Author 
 
Country of 
study 
First year of 
recruitment 
Regimens 
with which 
resistant 
patients 
were 
treated 
Treatment 
outcome 
reported? 
Relapse 
reported? 
Random 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants 
and 
personnel 
Blinding of 
outcome 
assessment 
Attrition Selective 
reporting 
HKCS
7
 Hong Kong 1978 HRSZ Yes Yes Unknown Unknown Unknown Unknown High High 
Jindani
8
 Benin, China, 
Guinea, 
Mozambique, 
Nepal, 
Tanzania 
1998 EHRZ/EH, 
EHRZ/HR  
Yes (but 
combined 
with 
relapse) 
Yes (but 
combined 
with 
treatment 
outcome) 
Low Low High High High High 
TRC
9
 India 1990 EHRZ/HR Yes No Unknown Unknown Unknown Unknown High High 
Table of included publications after the extraction stage. Quality assessment (risk of bias) utilised the framework of Higgins et al.
6
 XX/YY- indicates drugs 
present in initiation (X) versus continuation (Y) phase, E- ethambutol, H- isoniazid, HKCS- Hong Kong Chest Service, R- rifampicin, S- streptomycin, TB- 
tuberculosis, TRC- Tuberculosis Research Centre Madras, Z- pyrazinamide 
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Figure 1: Selection of papers for inclusion 
Selection strategy for systematic review. At full text extraction stage ‘not randomised’ relates to the 
functionality of randomisation for patients with DR disease (randomisation may have been broken). 
‘Only STM-R’ and ‘Only thiacetazone-R’ criteria refer to studies documenting outcomes specifically for 
patients with STM or thiacetazone resistant disease but not a relevant resistance pattern for this 
review. DR- drug resistance, MDR- multidrug resistant, R- resistant, RCT- randomised controlled trial, 
RMP- rifampicin, STM- streptomycin, TB- tuberculosis, WoS- Web of Science, XDR- extensively DR 
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ONLINE APPENDIX 1: Search strategy for randomised controlled trials 
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 
#1 exp Tuberculosis/  
#2 (TB or tuberculo*).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept 
word, unique identifier] 
 
#3 1 OR 2  
#4 exp Drug Therapy/  
#5 (treatment or therapy or therapeutic*).mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, keyword heading 
word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
 
#6 4 OR 5  
#7 exp controlled clinical trial/  
#8 exp Randomized Controlled Trial/  
#9 randomi#ed.mp.  
#10 trial.mp.  
#11 7 OR 8 OR 9 OR 10  
#12 3 AND 6 AND 11  
 
Web of Science 
#1 (Tuberculosis[MeSH Terms]) OR TB OR tuberculo* ~619,973 
#2 (Drug Therapy[MeSH Terms]) OR treatment OR therapy OR 
therapeutic* 
~21,168,564 
#3 (Controlled Clinical Trial[MeSH Terms]) OR (Randomized Controlled 
Trial[MeSH Terms]) OR randomized OR randomised OR trial 
~3,704,538 
#4 1 AND 2 AND 3 6,828 
 
Embase Classic+Embase 
#1 exp tuberculosis/  
#2 (TB or tuberculo*).mp. [mp=title, abstract, subject headings, heading 
word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
 
#3 1 OR 2  
#4 exp drug therapy/  
#5 (treatment or therapy or therapeutic*).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
 
#6 4 OR 5  
#7 exp controlled clinical trial/  
#8 randomi#ed.mp.  
#9 trial.mp.  
#10 7 OR 8 OR 9  
#11 3 AND 6 AND 10  
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ONLINE APPENDIX 2: Search strategy for observational studies 
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 
#1 exp Tuberculosis/ 168,941 
#2 (TB or tuberculo*).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept 
word, unique identifier] 
232,853 
#3 1 OR 2 234,398 
#4 exp Drug Therapy/ 1,142,884 
#5 (treatment or therapy or therapeutic*).mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, keyword heading 
word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
5,148,843 
#6 4 OR 5 5,591,774 
#7 exp Rifampin/ 15,838 
#8 (rifampicin or rifampin).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept 
word, unique identifier] 
25,143 
#9 7 OR 8 25,143 
#10 exp Drug Resistance/ 875,289 
#11 resistan*.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique 
identifier] 
1,026,177 
#12 10 OR 11 857,222 
#13 3 AND 6 AND 9 AND 12 2,415 
  
 
 
